Show simple item record

dc.contributor.authorSpain, L
dc.contributor.authorLarkin, J
dc.date.accessioned2017-04-10T16:08:30Z
dc.date.issued2016-06
dc.identifier.citationImmunotherapy, 2016, 8 (6), pp. 677 - 679
dc.identifier.issn1750-743X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/574
dc.identifier.eissn1750-7448en_US
dc.identifier.doi10.2217/imt.16.6en_US
dc.formatPrint
dc.format.extent677 - 679
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectMelanoma
dc.subjectAntibodies, Monoclonal
dc.subjectTreatment Outcome
dc.subjectImmunotherapy
dc.subjectSurvival Analysis
dc.subjectClinical Trials as Topic
dc.subjectCTLA-4 Antigen
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectProgrammed Cell Death 1 Receptor
dc.subjectDrug-Related Side Effects and Adverse Reactions
dc.subjectIpilimumab
dc.subjectB7-H1 Antigen
dc.subjectNivolumab
dc.titleWeighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
dc.typeJournal Article
rioxxterms.versionofrecord10.2217/imt.16.6
rioxxterms.licenseref.startdate2016-06en_US
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfImmunotherapy
pubs.issue6
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume8en_US
pubs.embargo.terms12 months
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record